Featured Research

from universities, journals, and other organizations

Drugs that flush out HIV may impair killer T cells, possibly hindering HIV eradication

Date:
August 14, 2014
Source:
PLOS
Summary:
Histone deacetylase (HDAC) inhibitors have shown promise in 'flushing out' HIV from latently infected cells, potentially exposing the reservoirs available for elimination by cytotoxic T lymphocytes (CTL), also called killer T cells. However, findings now suggest that treatment with HDAC inhibitors might suppress CTL activity and therefore compromise the 'kill' part of a two-pronged 'flush-and-kill' HIV eradication strategy.

Histone deacetylase (HDAC) inhibitors have shown promise in "flushing out" HIV from latently infected cells, potentially exposing the reservoirs available for elimination by cytotoxic T lymphocytes (CTL), also called killer T cells. However, findings published on August 14th in PLOS Pathogens now suggest that treatment with HDAC inhibitors might suppress CTL activity and therefore compromise the "kill" part of a two-pronged "flush-and-kill" HIV eradication strategy.

At least three different HDAC inhibitors, romidepsin, panobinostat, and SAHA, are under investigation as flushing agents. The individual drugs differ somewhat in their specificity for the 18 known human HDACs, and are also known to interact with other cellular factors and to alter the function of immune cells. Arguing that "this high degree of complexity both in terms of immunological outcomes and underlying mechanisms, necessitates that HDAC inhibitors be studied in a context that is matched to their intended utility," Brad Jones, from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, USA, and colleagues set out to test whether the three drugs affected the ability of CTL to eliminate HIV-infected target cells.

While the individual effects of the drugs on virus-specific CTL differ somewhat depending on specific assays, schedules, and doses, treatment with any of the three HDAC inhibitors impaired the ability of CTL to kill HIV-infected immune cells. All three drugs also rapidly suppressed CTL production of the key immune mediator interferon gamma.

Discussing the limitations of the study, the researchers state that, because their assays all involve drug treatment of CTL in cell culture settings, the extent to which HDAC inhibitors impact CTL function in HIV infected patients remains unknown. Consequently, they hope that their results will "motivate the incorporation of assays measuring ex-vivo T-cell function into ongoing and planned clinical trials of HDAC inhibitors, and that immunosuppression will be considered as a potential factor limiting the effectiveness of any observed outcomes." They also highlight the potential broader risk of treating HIV-positive individuals -- whose immune systems remain compromised even on antiretroviral therapy -- with HDAC inhibitors that have shown immunosuppressive activity in several studies, including this one.


Story Source:

The above story is based on materials provided by PLOS. Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard Brad Jones, Rachel O'Connor, Stefanie Mueller, Maria Foley, Gregory L. Szeto, Dan Karel, Mathias Lichterfeld, Colin Kovacs, Mario A. Ostrowski, Alicja Trocha, Darrell J. Irvine, Bruce D. Walker. Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes. PLoS Pathogens, 2014; 10 (8): e1004287 DOI: 10.1371/journal.ppat.1004287

Cite This Page:

PLOS. "Drugs that flush out HIV may impair killer T cells, possibly hindering HIV eradication." ScienceDaily. ScienceDaily, 14 August 2014. <www.sciencedaily.com/releases/2014/08/140814191945.htm>.
PLOS. (2014, August 14). Drugs that flush out HIV may impair killer T cells, possibly hindering HIV eradication. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2014/08/140814191945.htm
PLOS. "Drugs that flush out HIV may impair killer T cells, possibly hindering HIV eradication." ScienceDaily. www.sciencedaily.com/releases/2014/08/140814191945.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins